Menu Philippe sold $25K of SOPH
Menu Philippe (Chief Medical Officer) sold 5,000 shares of SOPHiA GENETICS SA (SOPH) at $4.95 on 2026-06-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new fact is the specific insider sale size, price, and 10b5-1 status; it does not include any new company performance or outlook information.
Market read
A disclosed insider sale can marginally influence sentiment, but 10b5-1 pre-arrangement usually reduces interpretive value.
What to watch
Traders may over-weight insider sales; without concurrent news (earnings, trial, guidance, financing), the signal is typically low.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS, filed via SEC EDGAR.
Ticker impact
SEC Form 4 shows SOPHiA GENETICS CMO Menu Philippe sold 5,000 shares in an open-market transaction on 2026-06-12 under a 10b5-1 plan.
Likely minimal price impact; any reaction should fade unless accompanied by other company-specific catalysts.
The disclosure is an insider sale (not a buy), explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes in the text.
Market effects
No sector-level read-across; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish fundamentals.
Key entities
- issuerSOPHiA GENETICS SA
Company whose insider transaction is disclosed on SEC Form 4.
- insiderMenu Philippe
Chief Medical Officer who executed an open-market sale of 5,000 shares under a 10b5-1 plan.
